By Associate Professor Hao-Wen Sim

Journal articles

Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European Journal of Cancer, 65, pp. 102 - 108, http://dx.doi.org/10.1016/j.ejca.2016.06.016

Sim H-W; Zadeh G; Mason WP; Aldape K; Bernstein M; Gentili F; Hodaie M; Kalia S; Kongkham PN; Zhang W; Tung T; Chen EX, 2016, 'Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues.', Journal of Clinical Oncology, 34, pp. 2028 - 2028, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.2028

Ruiz Morales JM; Swierkowski M; Wells C; Fraccon AP; La Russa F; Donskov F; Bjarnason GA; Lee J-L; Sim H-W; Beuselinck B; Wood L; Yuasa T; Pezaro CJ; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).', Journal of Clinical Oncology, 34, pp. 4510 - 4510, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4510

Li H; Kroeger N; de Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh HD; Rini BI; Knox JJ; Pantuck AJ; Choueiri TK; Heng DYC, 2016, 'The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.', Journal of Clinical Oncology, 34, pp. 552 - 552, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.552

Kröger N; Li H; De Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh H; Rini B; Knox J; Pantuck A; Choueiri T; Heng D, 2016, '756 Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies', European Urology Supplements, 15, pp. e756 - e756, http://dx.doi.org/10.1016/s1569-9056(16)60758-3

Lalani A-K; Li H; Heng D; Wood L; Kalirai A; Bjarnason G; Sim H-W; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa N, 2016, 'Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience', Annals of Oncology, 27, pp. vi285 - vi285, http://dx.doi.org/10.1093/annonc/mdw373.46

Tan LTY; Lewin JH; Urban D; Sim H-W; Hicks RJ; Byron K; Guccione L; Schaef E; Luen SJ; Tothill R; Schofield P; Bowtell D; Mileshkin LR, 2015, 'Retrospective review of the impact of a dedicated Cancer of Unknown Primary (CUP) clinic.', Journal of Clinical Oncology, 33, pp. e17680 - e17680, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e17680

Sim HW; Morris PG; Patil S; Khasraw M, 2014, 'Brain metastases in breast cancer', Expert Review of Anticancer Therapy, 14, pp. 173 - 183, http://dx.doi.org/10.1586/14737140.2014.863468

Back to profile page